5-alpha reductase type 1 Inhibitors
1 drugsAbout 5-alpha reductase type 1
5-alpha reductase type 1 (5αR1) converts testosterone to dihydrotestosterone (DHT), a potent androgen, and is one of two isoforms of this enzyme. Its distinct tissue distribution and enzymatic properties make it a target for drug development, modulating androgen-related pathways.
The rationale for targeting 5αR1 stems from its involvement in androgen metabolism. Currently, there is no genetic evidence available linking 5αR1 to specific diseases, but understanding its contribution to androgen metabolism is crucial.
There is one FDA-approved drug, AVODART, a small molecule targeting 5αR1, with applications categorized as 'other'. WAYLIS THERAP is the only company with an approved drug for this target.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Bladder Cancer with only 1 trials.
Top 5-alpha reductase type 1 Drugs
WAYLIS THERAP is the only company with an approved drug targeting 5-alpha reductase type 1.
Low competition suggests an opportunity for new entrants, but also indicates potential market risk.
5-alpha reductase type 1 Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets 5-alpha reductase type 1, using small molecule modality.
Explore alternative modalities like antibodies to differentiate from existing therapies.
5-alpha reductase type 1 Clinical Trials 52 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 19 | 16 | 2 | 1 | 89% |
| Phase 2 | 16 | 9 | 5 | 2 | 64% |
| Phase 3 | 8 | 6 | 0 | 2 | 100% |
| Phase 4 | 9 | 8 | 1 | 0 | 89% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
5-alpha reductase type 1 Drug Approval Timeline (2001 - 2001)
The first and most recent drug approval for this target was AVODART in 2001.
The lack of recent approvals indicates a potentially saturated market or challenges in drug development.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 34 clinical trials targeting 5-alpha reductase type 1.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities